Elsevier and eMolecules Collaboration Enables Easy Sourcing of Chemicals via Reaxys(R)

Enriched Content Offering Integrates Reaction and Substance Searching, Synthesis Planning and Chemical Procurement Into a Seamless Workflow

FRANKFURT, September 14, 2010 - Elsevier is pleased to announce that Reaxys now provides an
enriched commercial availability service, as a result of the ongoing
collaboration between the Reaxys development team and eMolecules. Chemical
procurement of commercially available compounds is now incorporated into the
reaction and substance search workflow. Research chemists can now immediately
access the eMolecules ordering page, complete with full quantity, pricing and
vendor information, all via the eMolecules icon. It becomes part of the
overall research workflow, the chemist can order the desired compound and
easily continue with their reaction or substance query.

Reaxys is Elsevier's web-based chemistry application which
combines reaction and substance data search and retrieval in organic,
organometallic, inorganic and physical chemistry with synthesis planning.
Reaxys allows research chemists to get important and relevant information
from journals and patents fast and conveniently in a single overview.

Mark van Mierle, MD of Elsevier Information Systems, said,
"Sourcing the right chemical at the best price and in an easy manner is
clearly a crucial step in a chemist's workflow. I believe this enhancement to
Reaxys will enable chemists to make better decisions and get back to the lab
more quickly."

Klaus Gubernator, CEO, eMolecules, added, "The collaboration
between Elsevier and eMolecules focuses on providing our customers with an
enhanced user experience, and the incorporation of all elements of the
chemist's workflow into one integrated system."

The Reaxys development team will continue to work with
eMolecules to further streamline all aspects of the commercial availability
process in order to bring the researchers the most relevant information with
fewer clicks.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com),
Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and
Nursing Consult (www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(www.scival.com) and MEDai's Pinpoint Review (www.medai.com),
which help research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier
(www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About eMolecules

eMolecules is the world's leading open-access chemical
structure search engine, providing chemistry eCommerce solutions for
suppliers of research chemicals and industrial and academic research
organizations. They deliver chemical building blocks and screening compounds
worldwide from any supplier in any requested physical format. They are the
most popular chemistry web site, distinguished by fast results, ease of use,
and up to date information about commercially available chemicals.

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed
Elsevier for the management of intellectual property. Elsevier Properties SA
owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including
Reaxys(R), PharmaPendium(TM), SciVal(TM) and The Lancet(R) are owned and
protected by Elsevier Properties SA and used under license. For additional
information see www.reedelsevier.com.

    Media Contact
    Tom Reller
    Vice President, Global Corporate Relations
    +1-215-239-3508
    T.Reller@Elsevier.com

Media Contact: Tom Reller, Vice President, Global Corporate Relations, +1-215-239-3508, T.Reller at Elsevier.com